PROTAC Library - PROTAC® / BOC Sciences

Structure	Catalog	Product Name	CAS	E3 Ligase	Target	Inquiry
	BPL-202313	2-(2,6-Dioxopiperidin-3-yl)-4-((2-(2-(2-(2-(4-(3-((4-((4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)sulfonyl)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)ethoxy)ethoxy)ethyl)amino)isoindoline-1,3-dione	2765641-93-6	CRBN	CDK2	Inquiry
Molecular Weight: 898.02 Molecular Formula: C43H51N11O9S Density: 1.45±0.1 g/cm3 Description: It is a selective CDK2 degrader that protects against cisplatin-and noise-induced hearing loss.
	BPL-202314	(2S,4R)-4-Hydroxy-1-((S)-2-(2-(2-(4-(3-((4-((4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl)amino)phenyl)sulfonyl)propyl)-1H-1,2,3-triazol-1-yl)ethoxy)acetamido)-3,3-dimethylbutanoyl)-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide	2765641-87-8	VHL	CDK2	Inquiry
Molecular Weight: 981.22 Molecular Formula: C48H60N12O7S2 Density: 1.38±0.1 g/cm3 Description: It is a selective CDK2 degrader that protects against cisplatin-and noise-induced hearing loss.
	BPL-202315	4-[(2,6-Difluorobenzoyl)amino]-N-[trans-4-[[1-[2-[2-[2-[2-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethyl]-1H-1,2,3-triazol-4-yl]methoxy]cyclohexyl]-1H-pyrazole-3-carboxamide	2765641-97-0	CRBN	CDK2	Inquiry
Molecular Weight: 876.88 Molecular Formula: C41H46F2N10O10 Density: 1.55±0.1 g/cm3 Description: It is a selective CDK2 degrader that protects against cisplatin-and noise-induced hearing loss.
	BPL-202316	4-(2,6-Difluorobenzamido)-N-(4-((1-(2-(2-(((S)-1-((2S,4R)-4-hydroxy-2-((4-(4-methylthiazol-5-yl)benzyl)carbamoyl)pyrrolidin-1-yl)-3,3-dimethyl-1-oxobutan-2-yl)amino)-2-oxoethoxy)ethyl)-1H-1,2,3-triazol-4-yl)methoxy)cyclohexyl)-1H-pyrazole-3-carboxamide	2765641-95-8	VHL	CDK2	Inquiry
Molecular Weight: 960.08 Molecular Formula: C46H55F2N11O8S Density: 1.47±0.1 g/cm3 Description: It is a selective CDK2 degrader that protects against cisplatin-and noise-induced hearing loss.
	BPL-202317	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentyl)piperidin-4-yl)-3-methoxybenzamide	2869057-02-1	CRBN	BRD4	Inquiry
Molecular Weight: 902.07 Molecular Formula: C48H59N11O7 Density: 1.45±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202318	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexyl)piperidin-4-yl)-3-methoxybenzamide	2869057-03-2	CRBN	BRD4	Inquiry
Molecular Weight: 916.08 Molecular Formula: C49H61N11O7 Density: 1.44±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202319	WWL0202	2869057-04-3	CRBN	BRD4	Inquiry
Molecular Weight: 930.12 Molecular Formula: C50H63N11O7 Density: 1.42±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202320	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)octyl)piperidin-4-yl)-3-methoxybenzamide	2869057-05-4	CRBN	BRD4	Inquiry
Molecular Weight: 944.15 Molecular Formula: C51H65N11O7 Density: 1.41±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202321	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(9-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)nonyl)piperidin-4-yl)-3-methoxybenzamide	2869057-07-6	CRBN	BRD4	Inquiry
Molecular Weight: 958.18 Molecular Formula: C52H67N11O7 Density: 1.40±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202322	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)decyl)piperidin-4-yl)-3-methoxybenzamide	2869057-08-7	CRBN	BRD4	Inquiry
Molecular Weight: 972.21 Molecular Formula: C53H69N11O7 Density: 1.39±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202323	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(11-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)undecyl)piperidin-4-yl)-3-methoxybenzamide	2869057-09-8	CRBN	BRD4	Inquiry
Molecular Weight: 986.23 Molecular Formula: C54H71N11O7 Density: 1.38±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202324	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(4-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)butyl)piperidin-4-yl)-3-methoxybenzamide	2869057-10-1	CRBN	BRD4	Inquiry
Molecular Weight: 945.10 Molecular Formula: C49H60N12O8 Density: 1.48±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202325	WWL0245	2869057-11-2	CRBN	BRD4	Inquiry
Molecular Weight: 873.97 Molecular Formula: C45H51N11O8 Density: 1.53±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202326	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(4-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)butanoyl)piperidin-4-yl)-3-methoxybenzamide	2869057-12-3	CRBN	BRD4	Inquiry
Molecular Weight: 902.03 Molecular Formula: C47H55N11O8 Density: 1.50±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202327	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)pentanoyl)piperidin-4-yl)-3-methoxybenzamide	2869057-13-4	CRBN	BRD4	Inquiry
Molecular Weight: 916.05 Molecular Formula: C48H57N11O8 Density: 1.48±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202328	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)hexanoyl)piperidin-4-yl)-3-methoxybenzamide	2869057-14-5	CRBN	BRD4	Inquiry
Molecular Weight: 930.08 Molecular Formula: C49H59N11O8 Density: 1.47±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202329	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(7-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)heptanoyl)piperidin-4-yl)-3-methoxybenzamide	2869057-15-6	CRBN	BRD4	Inquiry
Molecular Weight: 944.11 Molecular Formula: C50H61N11O8 Density: 1.45±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202330	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)glycyl)piperidin-4-yl)-3-methoxybenzamide	2869057-16-7	CRBN	BRD4	Inquiry
Molecular Weight: 859.01 Molecular Formula: C45H54N12O6 Density: 1.51±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202331	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(5-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)pentanoyl)piperidin-4-yl)-3-methoxybenzamide	2869057-17-8	CRBN	BRD4	Inquiry
Molecular Weight: 901.09 Molecular Formula: C48H60N12O6 Density: 1.46±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
	BPL-202332	4-(((R)-5-(Cyclohexylmethyl)-4-ethyl-1-methyl-4,5-dihydro-[1,2,4]triazolo[4,3-f]pteridin-7-yl)amino)-N-(1-(6-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)hexanoyl)piperidin-4-yl)-3-methoxybenzamide	2869057-18-9	CRBN	BRD4	Inquiry
Molecular Weight: 915.11 Molecular Formula: C49H62N12O6 Density: 1.44±0.1 g/cm3 Description: It is a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.